Organization
Precede Biosciences
2 abstracts
Abstract
Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer.Org: Dana-Farber Cancer Institute, Precede Biosciences, Harvard Medical School,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,